The introduction of the BCR-ABL inhibitor imatinib revolutionized the treatment of patients with chronic myeloid leukemia (CML). However, resistance to imatinib has become a clinically significant issue, limiting its long-term efficacy. Numerous mechanisms have been associated with imatinib resistance, including mutations to the BCR-ABL gene, increased production of BCR-ABL, and activation of BCR-ABL–independent pathways (e.g., SRC-family kinases [SFKs]). Resistance to imatinib has driven the development of second-line therapies, such as dasatinib, a dual BCR-ABL/SFK inhibitor more potent than imatinib at targeting BCR-ABL. Dasatinib is approved for the treatment of patients with imatinib-resistant and -intolerant CML and Philadelphia chromosome–positive acute lymphoblastic leukemia. Nilotinib, an analog of imatinib, more potent than its parent compound, is another approved agent for patients with imatinib-resistant or -intolerant CML in the chronic or accelerated phase. Nurses must be aware of what constitutes a requirement for treatment change and the mechanisms of resistance that inform the choice of second-line agents. Oncology nurses also must ensure that patients have been educated appropriately to understand imatinib resistance and second-line treatment options. This article explores the mechanisms and identification of resistance and treatment options for when resistance occurs, as well as nursing implications.

At a Glance
- Resistance to imatinib has become a significant clinical problem and has led to the development of second-line therapies, such as dasatinib and nilotinib.
- Nurses must be aware of what constitutes a requirement for treatment change and the mechanisms of resistance that inform the choice of second-line agents.
- Oncology nurses must ensure that patients are educated appropriately to understand imatinib resistance and available second-line treatment options.

Chronic myeloid leukemia (CML) is a clonal, myeloproliferative disorder of hematologic stem cells and accounts for 15% of adult leukemias in the United States (Jemal et al., 2007). CML progression usually occurs in three phases, including a chronic phase (CP) that most often is asymptomatic, an accelerated phase (AP), and a terminal blast phase (BP) (Sawyers, 1999). If CML is left untreated, progression from CP to BP usually occurs in three to five years (Sawyers). CML is characterized by a genetic translocation between chromosomes 9 and 22 (the Philadelphia chromosome). The translocation results in an abnormal fusion gene that encodes for the constitutively active BCR-ABL tyrosine kinase, the known causative agent underlying CML pathogenesis (Daley, Van Etten, & Baltimore, 1990; Faderl et al., 1999). The identification of this protein has made it an ideal target for therapeutic intervention.

The tyrosine kinase inhibitor (TKI) imatinib was the first BCR-ABL–targeted agent approved in 2001 for the treatment of patients with CML and has revolutionized the treatment of the disease. Unfortunately, resistance to imatinib has become a clinically significant problem that limits the long-term benefits of the drug in many patients with CML (Oestreicher, 2007a). The mechanisms that underlie imatinib resistance are multifactorial and should be considered carefully when healthcare professionals are choosing second-line treatment. This article discusses the